市场调查报告书

全球猪疫苗市场:各产品,各终端用户,各用途,各地区 - 成长,趋势,预测

Porcine Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 704727
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
Back to Top
全球猪疫苗市场:各产品,各终端用户,各用途,各地区 - 成长,趋势,预测 Porcine Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

本报告提供全球猪疫苗市场相关调查,汇整市场现状与今后的成长预测,各市场区隔趋势,各地区趋势,及加入此市场的主要企业的简介等资料。

第1章 简介

第2章 调查方法

第3章 摘要整理

第4章 主要推论

第5章 市场概要

  • 目前市场方案
  • 波特五力分析

第6章 促进要素,阻碍要素,机会,课题分析

  • 推动市场的要素
  • 阻碍市场的要素
  • 机会
  • 课题

第7章 市场区隔

  • 对象各疾病
    • 腹泻
    • 禽流感
    • 关节炎
    • 博德氏杆菌鼻炎
    • 猪繁殖·呼吸病毒
    • 猪环状病毒相关疾病
    • 其他
  • 各技术
    • 不活化疫苗
    • 活病毒疫苗
    • 类毒素疫苗
    • 重组疫苗
    • 共轭疫苗
    • DNA疫苗
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第8章 竞争环境

  • 合并·收购分析
  • 协定,联合,联盟
  • 新产品上市

第9章 主要加入企业

  • Bayer AG.
  • IDT Biologika GmbH
  • HIPRA
  • Ceva
  • Elanco
  • Arko Laboratories, LTD.
  • Intervet Inc.
  • Merial
  • Vetoquinol
  • Zoetis Services LLC.

第10章 市场未来

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 62881

The recent years have witnessed a significant increase in the demand for pork and gelatin, an increase in the prevalence of swine diseases, and growth in R&D expenditure for innovation of vaccines. According to the world meat consumption statistics provided by the US Department of Agriculture - Foreign Agricultural Service (USDA - FAS), 40.4% of the total meat consumption, across the globe, in 2017 is accounted for by pork alone. The report also states that per capita pork consumption (lb, carcass weight) has observed significant growth, across many regions, as shown in the graph.

This increase in pork consumption is expected to give rise to a growing need of keeping the swine population free from every possible disease that could affect swine and pose a threat to the human population, owing to the rise in prevalence of several zoonotic diseases. As a result of this, the requirement for a variety of swine vaccines, targeting various porcine diseases, is expected to grow.

Key Market Trends

Porcine Circovirus Associated Disease is Expected to Witness a Healthy Growth

PCV (Porcine Circovirus) is the smallest non-enveloped, single-stranded DNA virus, which replicates autonomously in eukaryotic cells, using the host polymerase for genome amplification. Generally, the price of vaccines targeting porcine circovirus associated disease (PCVAD) can range from USD 50 to around USD 500. Commercially available PCVAD vaccines can be of many types, mainly based upon the dosage, packaging size, age of the pig it is used on, and virus type. Some of the major brands manufacturing and selling porcine vaccines for PCVAD, globally, are Boehringer Ingelheim, Merck, and Zoetis, among others. The first FLEX Family swine vaccine for PCV2 protection in a single injection was Ingelvac CircoFLEX, by Boehringer Ingelheim. Hence, it is one of the revolutionary PCV2 vaccines in the market.

United States Holds a Significant Market Share

Increasing pork consumption, the growing prevalence of various swine diseases, and rising per capita animal healthcare expenditure are the factors due to which the United States is expected to retain its large market share.

Europe is the second-largest market for Porcine Vaccine is expected to follow North America, while Asia-Pacific is expected to demonstrate highest growth rate owing to factors such as increasing demand for animal-based food products, especially in South-East Asia, rise in awareness about porcine health, and recent advancements in the field of biotechnology. Hence, the aforementioned factors are expected to fuel the growth of the Porcine Vaccine Market in the Asia Pacific.

Competitive Landscape

The porcine vaccines market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence and are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition, due to a rapidly expanding market size, fueled by rising concerns over food safety and the increasing adoption of companion as well as farm animals.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growth in Demand for Pork and Gelatin
    • 4.2.2 Rise in Prevalence of Swine Diseases
    • 4.2.3 Increase in R&D Expenditure for Innovation of Vaccines
  • 4.3 Market Restraints
    • 4.3.1 High Expenses of Maintaining and Handling Storage Conditions
    • 4.3.2 Chance of Reverse Reaction from Vaccines
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Target Disease
    • 5.1.1 Diarrhea
    • 5.1.2 Swine Influenza
    • 5.1.3 Arthritis
    • 5.1.4 Bordetella Rhinitis
    • 5.1.5 Porcine Reproductive and Respiratory Syndrome (PRRS)
    • 5.1.6 Porcine Circovirus Associated Disease (PCVAD)
    • 5.1.7 Other Target Diseases
  • 5.2 By Technology
    • 5.2.1 Inactivated Vaccines
    • 5.2.2 Live Attenuated Vaccines
    • 5.2.3 Toxoid Vaccines
    • 5.2.4 Recombinant Vaccines
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 COMPANY PROFILES
    • 6.1.1 Bayer AG
    • 6.1.2 IDT Biologika GmbH
    • 6.1.3 HIPRA
    • 6.1.4 Ceva Sante Animale
    • 6.1.5 Elanco
    • 6.1.6 Arko Laboratories Ltd
    • 6.1.7 Intervet Inc.
    • 6.1.8 Merial
    • 6.1.9 Vetoquinol
    • 6.1.10 Zoetis Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top